Given the fact that the COL1‐CD133 interaction promotes the tumorigenesis of GSCs, further investigation of this pathway, including isolation of the inhibition of CD133‐COL1 interaction fragment, should provide an approach to anti‐GBM therapy. The gene discussed is PROM1; the disease is glioblastoma.